Summary

Great efforts have been invested worldwide to better understand and mitigate the impact of air pollution on human health. However, the debate about safe standards is still open. Aphekom, a multi-centre project funded by the European Commission (GA 2007105), aimed to describe the potential health benefits that would be achieved by meeting the World Health Organization air quality guidelines (WHO-AQG) for PM$_{10}$, fine particles (PM$_{2.5}$) and ozone. Short-term impacts of ozone and PM$_{10}$ on mortality and morbidity, as well as the long-term impact of PM$_{2.5}$ on mortality, life expectancy (LE) and monetary health benefits were quantified based on published concentration-response functions and economic values. Pollutants and health outcome data were recorded for the period 2004-2006.

Although annual mean of PM$_{10}$ for the study period did not exceed the legislative limit value in Europe (40 $\mu$g/m$^3$) in the city of Granada, our findings show that, in the short-term, compliance with WHO-AQG of 20 $\mu$g/m$^3$ would prevent each year more than 13 attributable deaths (6/100,000), and about 19 (8/100,000) and 9 (4/100,000) hospital admissions for respiratory and cardiovascular diseases, respectively in Granada. On the other hand, and although the impact of the levels of ozone on health registered in the city of Granada were not very high for the study period, an improvement in the precedents of this pollutant would avoid around 3 premature deaths and would also carry the reduction of some cases hospital admissions for respiratory causes, especially among elderly people.

Larger health benefits were recorded when considering a decrease in PM$_{2.5}$ concentrations at the long-term. The compliance with WHO-AQG of 10$\mu$g/m$^3$ in PM$_{2.5}$ annual mean would avoid more than 136 deaths (89/100,000) in Granada each year, accounting for a monetary health benefit of more than €225 millions annually. This decrease could add up to 9.3 months of life expectancy for persons 30 year of age and older.

Ours findings support the need to revise current air quality legislative limit values, especially in the case of fine particles PM$_{2.5}$. On the other hand, our results show that transportation keeps being the most relevant source of air pollution in Granada. More actions measurement needs to be taken in this direction to decrease current particulate matter concentrations to safer standards.

Major uncertainties in this study are related to the exposure characterization over the study period due to changes in the location of the monitoring stations during 2005.

Acronyms

Aphekom: Improving Knowledge and Communication for Decision Making on Air Pollution and Health in Europe

HIA: health impact assessment

O$_3$: ozone

PM$_{10}$: particulate matter with an aerodynamic diameter $<$10 $\mu$m

PM$_{2.5}$: particulate matter with an aerodynamic diameter $<$2.5 $\mu$m

Introduction

Much has been done in recent years in European cities to reduce air pollution and its harmful effects on health. Yet gaps remain in stakeholders’ knowledge and understanding of this continuing threat that hamper the planning and implementation of measures to protect public health more effectively.

Sixty Aphekom scientists have therefore worked for nearly 3 years in 25 cities across Europe to provide new information and tools that enable decision makers to set more effective European, national and local policies; health professionals to better advise vulnerable individuals; and all individuals to better protect their health.
Ultimately, through this work the Aphekom project hopes to contribute to reducing both air pollution and its impact on health and well being across European cities.

**Chapter 1. Standardised HIA in 25 Aphekom cities**

Health impact assessments (HIA) have been used to analyze the impact of improving air quality on a given population's health. Using standardised HIA methods, the preceding Apheis project (1) (www.apheis.org) showed that large health benefits could be obtained by reducing PM levels in 26 European cities totalling more than 40 million inhabitants (2;3). Apheis thus confirmed that, despite reductions in air pollution since the 1990s, the public health burden of air pollution remains of concern in Europe. The city of Granada was not participating in the Apheis project.

Building on the experience gained in the earlier Apheis project, Aphekom conducted a standardised HIA of urban air pollution in the 25 Aphekom cities totalling nearly 39 million inhabitants: Athens, Barcelona, Bilbao, Bordeaux, Brussels, Bucharest, Budapest, Dublin, Granada, Le Havre, Lille, Ljubljana, London, Lyon, Malaga, Marseille, Paris, Rome, Rouen, Seville, Stockholm, Strasbourg, Toulouse, Valencia and Vienna. In each participating centre, the project analysed the short-term impacts of ozone and PM10 on mortality and morbidity, as well as the long-term impacts of PM2.5 on mortality and life expectancy in populations 30 years of age and older.

This work shows that a decrease to 10 μg/m³ of long-term exposure to PM$_{2.5}$ fine particles (WHO's annual air-quality guideline) could add up to 22 months of life expectancy for persons 30 years of age and older, depending on the city and its average level of PM$_{2.5}$.

Hence, exceeding the WHO air-quality guideline on PM$_{2.5}$ leads to a burden on mortality of nearly 19,000 deaths per annum, more than 15,000 of which are caused by cardiovascular diseases.

Aphekom also determined that the monetary health benefits from complying with the WHO guideline would total some €31.5 billion annually, including savings on health expenditures, absenteeism and intangible costs such as well being, life expectancy and quality of life.
1.1. Description of the study area for GRANADA

Granada is a city in the autonomous community of Andalusia (South-East of Spain) located at the foot of the tallest mountain in the Iberian Peninsula, Sierra Nevada, and the confluence of three rivers, Beiro, Darro and Genil, at an average elevation of 685 metres above sea level. According to the Spanish Institute for Statistics, (in Spanish, INE), the population of the city of Granada was 239,154 inhabitants (46.43% men and 57% women) for year 2010, with an important presence of immigrants (6.3%) from Morocco and Central Africa. Since the 90's resident population has declined significantly, while there has been a strong demographic growth in the metropolitan belt towns (total population of 498,365 inhabitants for year 2009).

The eight hundred year-long Moorish civilization that lasted from year 711 till 1492 determines the layout of its narrow streets arranged in an intricate network. This is the case especially of the historical neighbourhoods of Albayzín and Real ejo, both spread out in hilly areas. However, the urban development of the city was very strong over 20th century leading to the emergence of vast new suburbs outside the historical city perimeter, located mostly in flat areas.

The Alhambra, a Moorish citadel and palace, is one of the most famous items of the Islamic historical legacy, making of Granada a hot spot among cultural and tourist cities in Spain. Granada is also well-known by its prestigious University, being considered as one of the three best cities for university students. In this way, the service sector represents a significant share of the local economy and is centred on tourism, trade and financial services. Industrial activity is concentrated in very few low-technology firms related to traditional agricultural activities and the food industry (oil and dairy).
Granada is served by a bus network which runs buses throughout the city as well as outlying the metropolitan area. However traffic jams are frequent due to the existing of a high car park (516 cars per 1,000 inhabitants) and the proper design of the city, with narrow streets. Recent urban planning designs and municipal orders are considering several measures to mitigate this situation like reducing car access to the city centre, or the construction of a metro-tram that will connect the metropolitan area and the city of Granada (its construction started in 2008 but still is ongoing).

The Aphekom project has defined the study area so that data from local air-quality monitoring can provide a good estimate of the average exposure of the population in the study area, taking into account local land use, daily commuting and meteorology.

Figure 2 represents an orthophoto of the studied area in the city of Granada, with a representation of the census geographic units (delimited by yellow lines) and the location of the air pollution monitoring stations used in the present study (red points).

Figure 2 – Orthophoto of the study area of the city of Granada

Climatology

Granada has a continental Mediterranean climate: cool in winter, with heavy frosts and hot summers with maximum temperatures above 35 ° C. The temperature variation is large throughout the year, often exceeding 20 ° C in a day. The rains, which are absent in summer, are concentrated in the winter and are rare during the rest of the year. These unique characteristics, which are more evident when compared with the climate of the subtropical coast of Granada (50 km far from Granada city), are due to its location between mountain ranges, and its average altitude of about 685 meters. In 2007, Granada was one of the fourth sunniest cities in Spain, with 3016 hours of sun (National Meteorological Agency, AEMET). For more details see data in Figure 3.
Population in the study area

During the study period, the population of the municipality of Granada was 236,982 inhabitants (110,041 men and 126,941 women) according to the population census published for year 2005 by the INE. The analysis of the population state by age for this period shows a greater concentration of people in the strata between 30 and 64 year of age, with a total proportion of 46.81%. The still greater proportion of people under 30 years (35.53%) than above 65 (17.66%) indicates a trend of demographic growth, possibly linked to the high immigration rates registered in the whole Andalusia over that period.

Commuting

Many people who works or spend a great part of their day time in the city of Granada, have their residency in the metropolitan belt towns. However, no data is currently available for quantifying this daily commuting rate.

1.2. Sources of air pollution and exposure data

Sources

Transportation constitutes the main source of air pollution in Granada and its metropolitan area: 54% of NO₂ and 66 to 68% of PM₁₀ and PM₂.₅, respectively, came from traffic sources (Table 1). In the case of SO₂ the contribution of this source has changed after the implementation of the fuel policy, decreasing from a 5% in 2004 to only 1% in 2005 and 2006. Most of the SO₂ emitted to the atmosphere in Granada was in fact related to industrial activity (70%).

Specific meteorological conditions like Saharan dust intrusions may have a punctual influence on maximum PM₁₀ levels but not on annual mean. This source of air pollution represents less than 2% of PM₁₀ annual mean.

Table 1 – Main sources of air pollution (expressed as tons/year). Data for year 2005

<table>
<thead>
<tr>
<th>Pollutant</th>
<th>Road</th>
<th>Domestic</th>
<th>Industry</th>
<th>Other sources (transportation other than road, incineration of garbage...)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SO₂</td>
<td>6.19</td>
<td>87.70</td>
<td>474.80</td>
<td>38.74</td>
</tr>
<tr>
<td>NO₂</td>
<td>1236.65</td>
<td>113.40</td>
<td>853.12</td>
<td>90.88</td>
</tr>
<tr>
<td>Primary PM₁₀</td>
<td>167.33</td>
<td>38.67</td>
<td>33.17</td>
<td>13.46</td>
</tr>
<tr>
<td>Primary PM₂.₅</td>
<td>136.61</td>
<td>36.72</td>
<td>16.69</td>
<td>11.01</td>
</tr>
</tbody>
</table>
Exposure data

The Surveillance System for Air Pollution is run by the Environment Department of the Regional Government of Andalusia.

As recommended in the Methodological Guidelines updated from that published in the Apheis-1 report, data were selected from background urban or suburban monitoring stations having at least 75% of valid values. The Air Quality Authorities at the Regional Government, in order to better characterize human exposure to ambient air pollution, run a passive diffusion tubes campaign in Granada during 2005 and established a new distribution for the air quality surveillance system. The proposed new location for the stations ensures a reasonable homogenous exposure measurements representative of the urban area of the city, where more than 80% of the population resides. Figure 2 represents the location of the monitoring stations used in this HIA report with red points: Paseillos Universitarios and Cartuja, catalogued as background urban or suburban stations, respectively. Those stations are different from the ones used before the study period, so it was impossible to provide with valid data for the whole period.

Automated method was used for PM$_{10}$ measurements (beta-radiation attenuation, UNE-EN 12341-1999) and for O$_3$ measurements (ultraviolet photometry, UNE 77 221:2000). PM$_{2.5}$ data have been calculated from PM$_{10}$ data, using the Apheis conversion factor of 0.7.

The whole study period covered a total of 1095 days from January 1st 2004 till December 31st 2006. For the city of Granada valid data for O$_3$ were registered only for 331 days, mostly during 2006 (Figure 4). In the case of daily mean PM$_{10}$ concentrations valid data were available for 574 days, with a percentage of days with valid data of 65.21% and 92.05% for years 2005 and 2006, respectively (Figure 5). According to the already mentioned methodological criteria, data from year 2005 had to be finally dismissed for HIA calculations purposes. The same approach was applied to PM$_{2.5}$ (Figure 6).

Table 2 shows the descriptive statistics of the three pollutants for the whole study period and the study area. The quality of air regarding PM$_{10}$ concentrations evolved positively from an annual mean value of 36 µg/m$^3$ in 2005 to 31 µg/m$^3$ in year 2006. However, more efforts need to be implemented since the fixed legal limit (Directive 1999/30/EC) for the daily mean concentration of PM$_{10}$ of 50 µg/m$^3$ was exceeded in almost 9 % of days with valid data (See Figure 5). Maximum daily mean concentrations of PM$_{10}$ in the study period reached the level of 155 µg/m$^3$ registered over winter 2005.

Table 2 – Daily mean levels, standard deviation and 5$^{th}$ and 95$^{th}$ percentiles for air pollutants (2004-2006)

<table>
<thead>
<tr>
<th>Pollutant</th>
<th>Daily mean ($\mu g/m^3$)</th>
<th>Standard deviation ($\mu g/m^3$)</th>
<th>5$^{th}$ percentile ($\mu g/m^3$)</th>
<th>95$^{th}$ percentile ($\mu g/m^3$)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ozone (daily 8h max)</td>
<td>65.38</td>
<td>23.35</td>
<td>25.00</td>
<td>101.50</td>
</tr>
<tr>
<td>PM$_{10}$ (daily average)</td>
<td>32.84</td>
<td>17.23</td>
<td>13.00</td>
<td>61.35</td>
</tr>
<tr>
<td>PM$_{2.5}$ (daily average)</td>
<td>22.99</td>
<td>12.06</td>
<td>9.10</td>
<td>42.95</td>
</tr>
</tbody>
</table>

The situation looks more severe when considering the World Health Organization Air Quality Guidelines (WHO-AQG) for human health protection that proposed an annual mean value of 20µg/m$^3$ for PM$_{10}$ and 10µg/m$^3$ for PM$_{2.5}$. According to these scenarios, in the city of Granada the annual average mean of PM$_{10}$ and PM$_{2.5}$ in the study period exceed WHO-AQG standards in 1.5 and 2.1 times, respectively.
The daily maximum 8-hour moving average concentrations for O₃ did not exceed the legal limit (Directive 2002/3/EC) of 120 μg/m³ in any moment of the study period (Table 2). However, considering the more protective standard of WHO-AQG established in 100μg/m³, maximum 8-hour moving average concentrations for O₃ were exceeded in 130 days over 2006, normally during the summer period (Figure 4).

Figure 4 – Ozone concentration in the study area for the city of Granada

Figure 5 – PM₁₀ concentration in the study area for the city of Granada
Mortality data for the study period (2004-2006) comes from the Regional Registry of Mortality, coded according to the International Classification of Diseases (ICD10). The group to be studied was restricted to city residents only. There were no missing data, and a quality control program was applied.

In the autonomous community of Andalusia most of the population is covered by the regional health system, although some people use private health services. Hospital admissions data on respiratory and cardiovascular causes come from the Andalusian Health Services Information Service, also coded using the International Classification of Diseases (ICD10). It is considered that the coverage for years 2004-2006 represented around 95% of the admissions in the city. Only admissions for residents of the city of Granada were selected. The diagnosis used was the one that motivated the admission reflected in the discharge report.

Table 3 shows annual mean number and annual rates of the health outcomes included in this HIA report: total mortality and cardiovascular mortality in population aged 30 years and over and total mortality excluding external causes and cardio-respiratory hospitalizations in general population.

The average number of deaths among people aged 30 years and over in Granada for the period 2004-2006 was 2115 (annual rate 1384 per 100,000), among which cardiovascular causes accounted for approximately 35% of the total. Regarding hospital admissions, data shows that respiratory diseases affect extensively people aged 65 years and over (≥ 65 yrs), with almost 36% of all hospital admissions for those causes.
Table 3 – Annual mean number and annual rate per 100,000 deaths and hospitalizations (2004-2006)

<table>
<thead>
<tr>
<th>Health outcome</th>
<th>ICD9</th>
<th>ICD10</th>
<th>Age</th>
<th>Annual mean number</th>
<th>Annual rate per 100,000</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-external mortality*</td>
<td>&lt; 800</td>
<td>A00-R99</td>
<td>All</td>
<td>2099</td>
<td>886</td>
</tr>
<tr>
<td>Total mortality</td>
<td>&lt; 800</td>
<td>A00-Y98</td>
<td>&gt; 30</td>
<td>2115</td>
<td>1384</td>
</tr>
<tr>
<td>Cardiovascular mortality</td>
<td>390-429</td>
<td>I00-I52</td>
<td>&gt; 30</td>
<td>783</td>
<td>513</td>
</tr>
<tr>
<td>Cardiac hospitalizations</td>
<td>390-429</td>
<td>I00-I52</td>
<td>All</td>
<td>1474</td>
<td>622</td>
</tr>
<tr>
<td>Respiratory hospitalizations</td>
<td>460-519</td>
<td>J00-J99</td>
<td>All</td>
<td>1569</td>
<td>662</td>
</tr>
<tr>
<td>Respiratory hospitalizations</td>
<td>460-519</td>
<td>J00-J99</td>
<td>15-64 yrs</td>
<td>565</td>
<td>238</td>
</tr>
<tr>
<td>Respiratory hospitalizations</td>
<td>460-519</td>
<td>J00-J99</td>
<td>≥ 65 yrs</td>
<td>565</td>
<td>238</td>
</tr>
</tbody>
</table>

* Non-external mortality excludes violent deaths such as injuries, suicides, homicides, or accidents.

1.4. Health impact assessment

Aphekom chose different scenarios to evaluate the health impacts of short- and long-term exposure to air pollution. The scenarios are detailed below for each air pollutant.

NOTE: Under no circumstances should HIA findings for the different air pollutants be added together because the chosen air pollutants all represent the same urban air pollution mixture and because their estimated health impacts may overlap.

The HIA method is detailed in Annex 1.

1.4.1. Short-term impacts of PM$_{10}$

For PM$_{10}$, we first considered a scenario where the annual mean of PM$_{10}$ is decreased by 5 $\mu$g/m$^3$, and then a scenario where the PM$_{10}$ annual mean is decreased to 20 $\mu$g/m$^3$, the WHO annual air quality guideline (WHO-AQG). The results are presented in Table 4 and 5 and illustrated in Figure 7.

Reducing annual mean levels of PM$_{10}$ to 20 $\mu$g/m$^3$ could lead to a reduction yearly of the total burden of mortality (excluding external causes) and the hospitalizations for respiratory and cardiovascular causes among general population in Granada which is about 2.2 times greater than the reduction that could be achieved by reducing the annual mean levels of PM$_{10}$ in the study period only by 5 $\mu$g/m$^3$. 
Table 4 – Potential benefits of reducing annual PM$_{10}$ levels on total non-external* mortality

<table>
<thead>
<tr>
<th>Scenarios</th>
<th>Annual number of attributable deaths avoided</th>
<th>Annual number of attributable deaths avoided per 100,000</th>
</tr>
</thead>
<tbody>
<tr>
<td>Decrease by 5 µg/m$^3$</td>
<td>6</td>
<td>3</td>
</tr>
<tr>
<td>Decrease to 20 µg/m$^3$</td>
<td>13</td>
<td>6</td>
</tr>
</tbody>
</table>

* Non-external mortality excludes violent deaths such as injuries, suicides, homicides, or accidents.

Table 5 – Potential benefits of reducing annual PM$_{10}$ levels on hospitalisations

<table>
<thead>
<tr>
<th>Scenarios</th>
<th>Respiratory hospitalizations</th>
<th>Cardiac hospitalizations</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total annual attributable admissions avoided</td>
<td>Annual number of attributable admissions avoided per 100 000</td>
</tr>
<tr>
<td>Decrease by 5 µg/m$^3$</td>
<td>9</td>
<td>4</td>
</tr>
<tr>
<td>Decrease to 20 µg/m$^3$</td>
<td>19</td>
<td>8</td>
</tr>
</tbody>
</table>

Figure 7 – Potential benefits of reducing annual PM$_{10}$ levels on mortality and on hospitalisations
1.4.2. Short-term impacts of ozone

For ozone, WHO set two guideline values for daily the maximum 8-hours mean. The interim target value (WHO-IT1) is set at 160 μg/m³. The purpose of the interim value is to define steps in the progressive reduction of air pollution in the most polluted areas. The second value, the air quality guideline value (WHO-AQG) is set at 100 μg/m³.

We first considered a scenario where all daily values above 160 μg/m³ were reduced to WHO-IT (160 μg/m³), then a scenario where all daily values above 100 μg/m³ were reduced to WHO-AQG (100 μg/m³), and lastly a scenario where the daily mean is decreased by 5 μg/m³.

Results for each of these scenarios are presented in Tables 6 & 7 and illustrated in Figure 8. Although the impact of the levels of ozone on health registered in the city of Granada were not very high for the study period, an improvement in the precedents of this pollutant would avoid around 3 premature deaths and would also carry the reduction of some cases hospital admissions for respiratory causes, especially among elderly people.

Table 6 – Potential benefits of reducing daily ozone levels on total non-external* mortality

<table>
<thead>
<tr>
<th>Scenarios</th>
<th>Total annual number of attributable deaths avoided</th>
<th>Annual number of attributable deaths avoided per 100 000</th>
</tr>
</thead>
<tbody>
<tr>
<td>8h max daily values &gt;160 μg/m³ = 160 μg/m³</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>8h max daily values &gt;100 μg/m³ = 100 μg/m³</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Decrease by 5 μg/m³</td>
<td>3</td>
<td>1</td>
</tr>
</tbody>
</table>

* Non-external mortality excludes violent deaths such as injuries, suicides, homicides, or accidents.

Table 7 – Potential benefits of reducing daily ozone levels on hospitalizations

<table>
<thead>
<tr>
<th>Scenarios</th>
<th>Respiratory hospitalizations (15-64)</th>
<th>Respiratory hospitalizations (&gt;64)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total annual number of attributable admissions avoided</td>
<td>Annual number of attributable admissions avoided per 100 000</td>
</tr>
<tr>
<td>8h max daily values &gt;160 μg/m³ = 160 μg/m³</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>8h max daily values &gt;100 μg/m³ = 100 μg/m³</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Decrease by 5 μg/m³</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>
1.4.3. Long-term impacts of PM$_{2.5}$

For PM$_{2.5}$, we first considered a scenario where the PM$_{2.5}$ annual mean is decreased by 5 μg/m$^3$, and then a scenario where the PM$_{2.5}$ annual mean is decreased to 10 μg/m$^3$ (WHO AQG). Results for each of these scenarios are presented in Tables 8 & 9 and illustrated in Figure 9 & 10.

Table 8 – Potential benefits of reducing annual PM$_{2.5}$ levels on total mortality and on life expectancy (years)

<table>
<thead>
<tr>
<th>Scenarios</th>
<th>Total annual number of attributable deaths avoided</th>
<th>Annual number of attributable deaths avoided per 100 000</th>
<th>Gain in life expectancy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Decrease by 5 μg/m$^3$</td>
<td>61</td>
<td>40</td>
<td>0.3</td>
</tr>
<tr>
<td>Decrease to 10 μg/m$^3$</td>
<td>136</td>
<td>89</td>
<td>0.8</td>
</tr>
</tbody>
</table>

Table 9 – Potential benefits of reducing annual PM$_{2.5}$ levels on total cardiovascular mortality

<table>
<thead>
<tr>
<th>Scenarios</th>
<th>Total annual number of attributable deaths avoided</th>
<th>Annual number of attributable deaths avoided per 100 000</th>
</tr>
</thead>
<tbody>
<tr>
<td>Decrease by 5 μg/m$^3$</td>
<td>43</td>
<td>28</td>
</tr>
<tr>
<td>Decrease to 10 μg/m$^3$</td>
<td>95</td>
<td>62</td>
</tr>
</tbody>
</table>
Figure 9 – Potential benefits of reducing annual PM$_{2.5}$ levels on mortality

Figure 10 – Potential benefits of reducing annual PM$_{2.5}$ levels on life expectancy
1.4.4. Economic valuation

These HIAs provide short- and long-term potential benefits on mortality of reducing air pollution as well as the short-term potential benefits on hospitalisations.

**Mortality**

The monetary values chosen to assess mortality benefits differ depending on the short- or long-term nature of the exposure to air pollution (see Appendix 2). For attributable deaths avoided due to short-term exposure to air pollution the monetary cost was estimated at €86,600. According to this, the monetary health benefits resulted from a reduction in the annual mean level of PM$_{10}$ in the city of Granada by 5 μg/m$^3$ would total some € 0.54 millions annually. This benefit would increase up to € 1.5 millions when considering a reduction in the annual mean level of PM$_{10}$ to 20 μg/m$^3$.

Larger monetary health benefits were recorded when considering a decrease in PM$_{2.5}$ concentrations at the long-term. The compliance with WHO-AQG of 10 μg/m$^3$ in annual mean would account for a monetary health benefit of more than € 225 millions annually.

NOTE: the valuation of mortality benefits is based on stated preferences studies and will use common values for all cities together. Indeed, accounting for differences in country’s GNP per capita seems ethically unacceptable to stand for the valuation of life benefits.

**Hospitalisations**

The standard cost of illness approach is used for short-term hospitalisations, and consists in applying unit economic values to each case, including direct and indirect costs. The unit economic values will differ across cities, based on specific local market prices for medical resources and wages (see Appendix 2). The economic benefits related to a reduction in air pollution exposure are then computed by multiplying the number of hospitalisations in your city by the corresponding unit economic value.

1.4.5. Interpretation of findings

In this report the APHEKOM team has derived estimates of the health impact of both short- and long-term exposure to particles and ozone. These impacts have been estimated as the numbers of deaths and admissions attributable to air pollution avoided under different reduction scenarios. Further, these benefits have been quantified in monetary terms. Whilst there remains uncertainty in the health impact assessment and in their monetary quantification these results illustrate the magnitude of the potential benefits associated with reductions in air pollution in Granada and more widely across Europe. It should be noted that the benefits reported are not considered to be independent of each other and are therefore not additive across pollutants.

Although annual mean of PM$_{10}$ for the study period did not exceed the legislative limit value in Europe (40 μg/m$^3$) in the city of Granada, our findings show that, in the short-term, compliance with WHO-AQG of 20 μg/m$^3$ would prevent each year more than 13 attributable deaths (6/100,000), and about 19 (8/100,000) and 9 (4/100,000) hospital admissions for respiratory and cardiovascular diseases, respectively in Granada. On the other hand, and although the impact of the levels of ozone on health registered in the city of Granada were not very high for the study period, an improvement in the precedents of this pollutant would avoid around 3 premature deaths and would also carry the reduction of some cases hospital admissions for respiratory causes, especially among elderly people.

Larger health benefits were recorded when considering a decrease in PM$_{2.5}$ concentrations at the long-term. The compliance with WHO-AQG of 10μg/m$^3$ in PM$_{2.5}$ annual mean would avoid more than 136 deaths (89/100,000) in Granada each year, accounting for a monetary health benefit of more than € 225 millions annually. This decrease could add up to 9.3 months of life expectancy for persons 30 year of age and older.
Ours findings support the need to revise current air quality legislative limit values, especially in the case of fine particles PM$_{2.5}$. On the other hand, our results show that transportation keeps being the most relevant source of air pollution in Granada. More actions measurement needs to be taken in this direction to decrease current particulate matter concentrations to safer standards.

Major uncertainties in this study are related to the exposure characterization over the study period due to changes in the location of the monitoring stations during 2005.

Chapter 2. Health Impacts and Policy: Novel Approaches

Pollutants such as ultrafine particles occur in high concentrations along streets and roads carrying heavy traffic. And evidence is growing that living near such streets and roads may have serious health effects, particularly on the development of chronic diseases. Until now, however, HIAs have not explicitly incorporated this factor.

For this purpose, Aphekom has applied innovative HIA methods to take into account the additional long-term impact on the development of chronic diseases from living near busy roads. We also evaluated the monetary costs associated with this impact.

We first determined that, on average, over 50 percent of the population in the 10 European cities studied lives within 150 metres of roads travelled by 10,000 or more vehicles per day and could thus be exposed to substantial levels of toxic pollutants.

<table>
<thead>
<tr>
<th>City</th>
<th>Population (Million. Hab)</th>
<th>PM$_{10}$ annual average (ug/m$^3$)</th>
<th>% population within 75m (average 29%)</th>
<th>% population within 150m (average 52%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Granada</td>
<td>0.24</td>
<td>34</td>
<td>14%</td>
<td>28%</td>
</tr>
<tr>
<td>Ljubljana</td>
<td>0.27</td>
<td>32</td>
<td>23%</td>
<td>47%</td>
</tr>
<tr>
<td>Bilbao</td>
<td>0.31</td>
<td>27</td>
<td>29%</td>
<td>59%</td>
</tr>
<tr>
<td>Sevilla</td>
<td>0.7</td>
<td>41</td>
<td>20%</td>
<td>38%</td>
</tr>
<tr>
<td>Valencia</td>
<td>0.74</td>
<td>46</td>
<td>44%</td>
<td>71%</td>
</tr>
<tr>
<td>Brussels</td>
<td>1.03</td>
<td>29</td>
<td>37%</td>
<td>64%</td>
</tr>
<tr>
<td>Stockholm</td>
<td>1.3</td>
<td>17</td>
<td>14%</td>
<td>30%</td>
</tr>
<tr>
<td>Barcelona</td>
<td>1.53</td>
<td>33</td>
<td>56%</td>
<td>77%</td>
</tr>
<tr>
<td>Vienna</td>
<td>1.66</td>
<td>25</td>
<td>36%</td>
<td>62%</td>
</tr>
<tr>
<td>Rome</td>
<td>2.81</td>
<td>37</td>
<td>22%</td>
<td>43%</td>
</tr>
</tbody>
</table>

Figure 11 – Estimated percentage of people living near busy roads

In the cities studied, our HIA showed that living near these roads could be responsible for some 15-30 percent of all new cases of: asthma in children; and of COPD (chronic obstructive pulmonary disease) and CHD (coronary heart disease) in adults 65 years of age and older.
Aphekom further estimated that, on average for all 10 cities studied, 15-30 percent of exacerbations of asthma in children, acute worsening of COPD and acute CHD problems in adults are attributable to air pollution. This burden is substantially larger than previous estimates of exacerbations of chronic diseases, since it has been ignored so far that air pollution may cause the underlying chronic disease as well.

Figure 12 – Percentage of population with chronic diseases whose disease is attributable to living near busy streets and roads in 10 Aphekom cities

Figure 13 – Comparison of impact of air pollution on chronic diseases calculated using two different HIA approaches in Aphekom
In addition, for the population studied Aphekom estimated an economic burden of more than €300 million every year attributable to chronic diseases caused by living near heavy traffic. This burden is to be added to some €10 million attributable to exacerbations of these diseases.

The economic valuation is not sufficiently robust at the city level from a HIA as well as an economic perspective to allow for local computations.

Chapter 3. Health Impacts of Implemented Policies in Air Pollution

Beyond reviewing the documented benefits to health of the historic Dublin coal ban in 1990 and the recent implementation of congestion charges in London and Stockholm, Aphekom investigated the effects of EU legislation to reduce the sulphur content of fuels (mainly diesel oil used by diesel vehicles, shipping and home heating).

Our analysis in 20 cities showed not only a marked, sustained reduction in ambient SO$_2$ levels but also the resulting prevention of some 2,200 premature deaths valued at €192 million.

![Figure 14](image-url) – Yearly urban background SO$_2$ averages for 13 Aphekom cities from 1990 to 2004

Figures 15 and Figure 16 show preliminary work done using hourly SO$_2$ data from Vienna, Austria showing seasonal plots for winter (Fig.15) and summer (Fig 16) for a central urban station for the years 1990 to 2000. For example: In Figure 15 SO$_2$ levels are showing a general decreasing trend over time. The two peaks observed consistently throughout all years between 6am and noon and as well between 4pm and 11pm for the winter plots (Fig. 15) suggest that those peaks are mainly caused by traffic due to the morning and evening rush hours and as well due to space heating especially in the evenings. Comparing the two seasons the summer plot (Fig. 16) shows a clear reduction in peak SO$_2$ levels for the mentioned time periods. This might indicate the proportion of SO$_2$ that resulted from emissions due to heating during the winter months especially as high SO$_2$ levels are observed for a
few consecutive hours from ~5pm up to midnight coinciding with inversion. The smaller peaks are still observed again coinciding with the morning and evening rush hours and also reflecting climatic effects.

In Fig. 15 the observed winter SO$_2$ levels for the central urban station in Vienna in 1990 are markedly higher than later years and even though if the peak patterns look like in the other years the observed high SO$_2$ levels do not necessarily have to be caused by traffic! It is not clear, if these high SO$_2$ values were reached due to high sulphur content in diesel fuel for vehicles or due to other sources, such as fuel oil combustion, heating, being emitted simultaneously with the traffic related emissions.

![Winter hourly SO$_2$ for Stephansplatz (central urban station) Vienna 1990 - 2000](image.png)

**Figure 15 – Diurnal plot of winter hourly SO$_2$ for a central urban station in Vienna 1990-2000**

Figure 17 shows a 24hr-plot of hourly SO$_2$ data from an urban background station in London averaged for the winter months. In comparison to the pattern observed in Fig. 15 for Vienna, where 2 distinct peaks throughout the day for the winter months were observed, here in Fig. 17 levels tend to rise markedly in the morning hours and then entering a plateau period with minor variations during day time and declining from 6pm in the evening in 1992 to 1998. One possible explanation for these elevated SO$_2$ levels during midday might be that it reflects the metropolitan life-style of the city involving constant traffic use. This constant traffic might have been picked up by the urban background measuring station as London Bloomsbury is very central in the city centre.
Figure 16 – Diurnal plot of summer hourly SO\textsubscript{2} for a central urban station in Vienna 1990-2000

Figure 17 – Diurnal plot of winter hourly SO\textsubscript{2} for an urban background station in London 1992-1998
Valuation of the benefits of EU legislation to reduce the sulphur content of fuels

The local estimates are not sufficiently robust at the city level to allow a local HIA so it has been decided to use the meta-results for the local economic valuation. The legislation has two potential effects on mortality: short-term and long-term. It was decided that, to take a conservative standpoint, mortality effects would be considered as short-term effects. The value of a life year (VOLY) was estimated to be €86,600. Our analysis in 20 cities showed not only a marked, sustained reduction in ambient SO2 levels but also the resulting prevention of some 2,200 premature deaths valued at €192 million. The economic evaluation thus constitutes a lower bound of the mortality benefits of the legislation.

Chapter 4. Sharing Knowledge and Uncertainties with Stakeholders

Uncertainties perceived by scientists, policy makers and other stakeholders can undermine their confidence in the findings of HIAs. For this reason, Aphekom has developed a method that helps them discuss and share their views on both the uncertainties in HIA calculations and their impact on the decision-making process.

In addition, to help decision makers draft policies on air quality and related environmental-health issues, Aphekom has developed a process, based on a deliberation-support tool, that helps frame and structure exchanges between stakeholders working together. Using this process enables them to propose and discuss multiple criteria for evaluating, prioritising and aligning their various needs, and for choosing actions that match their objectives and preferences.

Chapter 5. Overview of findings and local recommendations

Great efforts have been invested worldwide to better understand and mitigate the impact of air pollution on human health. However, the debate about safe standards is still open. Aphekom, a multi-centre project funded by the European Commission (GA 2007105), aimed to describe the potential health benefits that would be achieved by meeting the World Health Organization air quality guidelines (WHO-AQG) for PM10, fine particles (PM2.5) and ozone. Short-term impacts of ozone and PM10 on mortality and morbidity, as well as the long-term impact of PM2.5 on mortality, life expectancy (LE) and monetary health benefits were quantified based in published concentration-response functions and economic values. Pollutants and health outcome data were recorded for the period 2004-2006.

Although annual mean of PM10 for the study period did not exceed the legislative limit value in Europe (40 μg/m³) in the city of Granada, our findings show that, in the short-term, compliance with WHO-AQG of 20 μg/m³ would prevent each year more than 13 attributable deaths (6/100,000), and about 19 (8/100,000) and 9 (4/100,000) hospital admissions for respiratory and cardiovascular diseases, respectively in Granada. On the other hand, and although the impact of the levels of ozone on health registered in the city of Granada were not very high for the study period, an improvement in the precedents of this pollutant would avoid around 3 premature deaths and would also carry the reduction of some cases hospital admissions for respiratory causes, especially among elderly people.

Larger health benefits were recorded when considering a decrease in PM2.5 concentrations at the long-term. The compliance with WHO-AQG of 10μg/m³ in PM2.5 annual mean would avoid more than 136 deaths (89/100,000) in Granada each year, accounting for a monetary health benefit of more than € 225 millions annually. This decrease could add up to 9.3 months of life expectancy for persons 30 year of age and older.

Ours findings support the need to revise current air quality legislative limit values, especially in the case of fine particles PM2.5. On the other hand, our results show that transportation keeps being the most relevant source of air pollution in Granada. More actions measurement needs to be taken in this direction to decrease current particulate matter concentrations to safer standards.
Major uncertainties in this study are related to the exposure characterization over the study period due to changes in the location of the monitoring stations during 2005.

References

*Agencia Estatal de Meteorología. Available at: http://www.aemet.es/es/portada (access on: 04.04.2011)*

Acknowledgements

Authors thank all the professionals and institutions that have made this study possible by providing the essential data, in particular to Juan Contreras, Antonio Lozano and Pilar Sánchez-Lechuga from the Department of Environment of the Regional Government of Andalusia; Jose Mª Mayoral from the Department of Public Health of the Regional Government of Andalusia; and Pedro Herrera from Traffic Control Centre of Granada.
Appendix 1 – Health impact assessment

For each specific relationship between health outcomes and pollutants, the health impact function was

$$\Delta y = y_0 (1 - e^{-\beta \Delta x})$$

where $\Delta y$ is the outcome of the HIA

$y_0$ is the baseline health data

$\Delta x$ is the decrease of the concentration defined by the scenario

$\beta$ is the coefficient of the concentration response function ($\beta = \log(\text{RR per } 10 \mu g/m^3)/10$)

The impact of a decrease of the pollutant concentration on the life expectancy was computed using standard abridged (5-year age groups) life table methodology, using the mortality data for each age group. We applied a reduction factor to the mortality rate, noted $n D_x$, according to

$$n D_{x,\text{impacted}} = n D_x e^{-\beta \Delta x}$$

$\Delta x$ is the decrease of the concentration defined by the scenario

$\beta$ is the coefficient of the concentration response function.

Concentration response functions (CRFs) were selected from the literature, favouring multi-cities studies located in Europe (Table 1).

<table>
<thead>
<tr>
<th>HIA</th>
<th>Health outcome</th>
<th>Ages</th>
<th>RR per 10 $\mu g/m^3$</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td>Short-term impacts of PM10</td>
<td>Non-external mortality</td>
<td>All</td>
<td>1.006 [1.004-1.008]</td>
<td>(4)</td>
</tr>
<tr>
<td></td>
<td>Respiratory hospitalizations</td>
<td>All</td>
<td>1.0114 [1.0062-1.0167]</td>
<td>(5)</td>
</tr>
<tr>
<td></td>
<td>Cardiac hospitalizations</td>
<td>All</td>
<td>1.006 [1.003-1.009]</td>
<td>(5)</td>
</tr>
<tr>
<td>Short-term impacts of O3</td>
<td>Non-external mortality</td>
<td>All</td>
<td>1.0031 [1.0017-1.0052]</td>
<td>(6)</td>
</tr>
<tr>
<td></td>
<td>Respiratory hospitalizations</td>
<td>15-64</td>
<td>1.001 [0.991-1.012]</td>
<td>(4)</td>
</tr>
<tr>
<td></td>
<td>Respiratory hospitalizations</td>
<td>&gt;=65</td>
<td>1.005 [0.998-1.012]</td>
<td>(4)</td>
</tr>
<tr>
<td>Long-term impacts of PM2.5</td>
<td>Total mortality</td>
<td>&gt;30</td>
<td>1.06 [1.02-1.11]</td>
<td>(7)</td>
</tr>
<tr>
<td></td>
<td>Cardiovascular mortality</td>
<td>&gt;30</td>
<td>1.12 [1.08-1.15]</td>
<td>(8)</td>
</tr>
</tbody>
</table>

For PM10, we first considered a scenario where the annual mean of PM10 is decreased by 5 $\mu g/m^3$, and then a scenario where the same PM10 annual mean is decreased to 20 $\mu g/m^3$, the WHO air quality guideline (WHO-AQG). The exposure indicator of PM10 was the annual mean, calculated as the arithmetic mean of the daily concentrations of the selected stations. The corresponding $\Delta x$ for the two scenarios are:
- Scenario 1, $\Delta x = 5 \mu g/m^3$
- Scenario 2, $\Delta x = ([PM10]_{mean} - 20 \mu g/m^3)$. 
  $\Delta x = 0$ if $[PM10]_{mean} < 20$

**Ozone**

For ozone, WHO set two values for the daily maximum 8-hours mean. The interim target value (WHO-IT1) is set at 160 $\mu g/m^3$. The purpose of the interim value is to define steps in the progressive reduction of air pollution in the most polluted areas. The air quality guideline value (WHO-AQG) is set at 100 $\mu g/m^3$.

We first considered a scenario where all daily values above 160 $\mu g/m^3$ were reduced to WHO-IT (160 $\mu g/m^3$), then a scenario where all daily values above 100 $\mu g/m^3$ were reduced to WHO-AQG (100 $\mu g/m^3$), and lastly a scenario where the daily mean is decreased by 5 $\mu g/m^3$.

The exposure indicator of ozone was the cumulated sum over defined thresholds, calculated using 8-hours-daily values.

The corresponding $\Delta x$ for the two scenarios are;

- Scenario 1, if $[O_3]_i \geq 160 \mu g/m^3$, $O_i = ([O_3]_i - 160)$
  if $[O_3]_i < 160 \mu g/m^3$, $O_i = 0$
- Scenario 2, if $[O_3]_i \geq 100 \mu g/m^3$, $O_i = ([O_3]_i - 100)$
  if $[O_3]_i < 100 \mu g/m^3$, $O_i = 0$
- Scenario 3, where the ozone yearly mean is decreased by 5 $\mu g/m^3$, $\Delta x = 5 \mu g/m^3$

**PM2.5**

For PM2.5, we first considered a scenario where the PM2.5 annual mean is decreased by 5 $\mu g/m^3$, and then a scenario where the PM2.5 annual mean is decreased to 10 $\mu g/m^3$ (WHO annual AQG). The exposure indicator of PM2.5 was the yearly mean, calculated as the arithmetic mean of the daily concentrations of the selected stations. The corresponding $\Delta x$ for the two scenarios are;

- Scenario 1, $\Delta x = 5 \mu g/m^3$
- Scenario 2, $\Delta x = ([PM2.5]_{mean} - 10 \mu g/m^3)$
  $\Delta x = 0$ if $[PM2.5]_{mean} < 10$

**References**


Appendix 2 – Economic valuation

Because the air pollution measures as well as epidemiologic data cover the 2004-2006 period for most of the cities, all costs are consequently expressed in euros 2005. Similarly, the average lengths of stay in hospital required for the benefits computations are for 2005.

Valuation of mortality benefits

Regarding mortality, we follow the standard valuation procedure adopted in Cafe (2005), NexExt (2003), ExternE (2000), which consists in using a Value of a Statistical Life (VSL) and a Value of a Life Year (VOLY) derived from stated preferences surveys, hence relying on preference-derived values rather than market-derived values. We chose to rely on values obtained in recent European studies (see final Aphekom report for more details).

The choice of the monetary value to assess mortality benefits associated to a decrease in air pollution level depends on the type of impact.

- For short-term mortality calculations, the annual number of deaths postponed per year is used. Because the gains in life expectancy corresponding to each of these postponed deaths can be considered in the range of a few months, certainly lower than one year (Cafe 2005, Vol 2, p. 46), a VOLY of €86,600 is applied to each deaths postponed to compute annual benefits.

- For long-term mortality calculations, the magnitude of the gain in life expectancy related to the deaths postponed is considered as higher than a year (see Ezzati et al., 2002; Hurley et al. 2005; Watkiss et al. 2005; or Janke et al., 2009). A VSL of €1,655,000 is applied to each deaths postponed to compute annual benefits.

- For long-term life expectancy calculations, an average gain in life expectancy for persons 30 years of age is also computed using life tables and following a cohort until complete extinction. The annual corresponding benefits are obtained by multiplying the average gain in life expectancy by the number of 30-year-old individuals in the city, and by the VOLY. This corresponds to the benefits (in terms of life expectancy) 30 year-old people would gain over their lifetime if exposed to the 10 µg/m³ average annual level of PM2.5 (WHO’s Air Quality Guideline) instead of the current existing air pollution level in the city.

Valuation of hospitalisations benefits

The standard cost of illness approach is used for acute hospitalisations, and consists in applying unit economic values approach to each case, including direct medical and indirect costs.

The direct medical costs related to cardiac and respiratory hospitalisations are computed as the cost per inpatient day times the average length of stay in hospital. These cost data are taken from CEC (2008) for all twelve countries where the cities analysed in Aphekom are located (see Table 1). The average lengths of stay in days are obtained from the OECD Health Database (2010) for all countries except Romania (which is imputed from the population weighted average lengths of the 11 other countries).

The indirect costs are computed as the average gross loss of production per day times twice the average length of stay in hospital. Since we cannot control whether these days were actual working days, we then compute the daily loss of production as the average gross earnings in industry and services (full employment) obtained from Eurostat (2003) for each country, expressed in 2005 and divided by 365 days.

The total medical costs for cardiac and respiratory hospitalisations are obtained by adding together the direct and indirect components.
Table 1  Average lengths of stay, daily hospitalisation costs and work loss, and total hospitalisation cost per patient.

<table>
<thead>
<tr>
<th>Country</th>
<th>Circulatory system</th>
<th>Respiratory system</th>
<th>Average length of stay in days (a)</th>
<th>Average cost per day (€ 2005)</th>
<th>Total costs related to hospitalisation (€ 2005)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Austria</td>
<td>8.2</td>
<td>6.6</td>
<td>319</td>
<td>83</td>
<td>3,977</td>
</tr>
<tr>
<td>Belgium</td>
<td>9.2</td>
<td>8.8</td>
<td>351</td>
<td>98</td>
<td>5,032</td>
</tr>
<tr>
<td>France</td>
<td>7.1</td>
<td>7.1</td>
<td>366</td>
<td>83</td>
<td>3,777</td>
</tr>
<tr>
<td>Greece</td>
<td>7.0</td>
<td>5.0</td>
<td>389</td>
<td>48</td>
<td>3,395</td>
</tr>
<tr>
<td>Hungary</td>
<td>7.4</td>
<td>6.5</td>
<td>59</td>
<td>18</td>
<td>703</td>
</tr>
<tr>
<td>Ireland</td>
<td>10.5</td>
<td>6.9</td>
<td>349</td>
<td>81</td>
<td>5,366</td>
</tr>
<tr>
<td>Italy</td>
<td>7.7</td>
<td>8.0</td>
<td>379</td>
<td>62</td>
<td>3,873</td>
</tr>
<tr>
<td>Romania</td>
<td>8.5(d)</td>
<td>7.4(d)</td>
<td>57</td>
<td>6</td>
<td>587</td>
</tr>
<tr>
<td>Slovenia</td>
<td>8.6</td>
<td>7.3</td>
<td>240</td>
<td>34</td>
<td>2,649</td>
</tr>
<tr>
<td>Spain</td>
<td>8.5</td>
<td>7.4</td>
<td>321</td>
<td>55</td>
<td>3,664</td>
</tr>
<tr>
<td>Sweden</td>
<td>6.0</td>
<td>5.2</td>
<td>427</td>
<td>92</td>
<td>3,666</td>
</tr>
<tr>
<td>United Kingdom</td>
<td>11.4</td>
<td>8.0</td>
<td>581</td>
<td>116</td>
<td>9,268</td>
</tr>
</tbody>
</table>

Mean(d) 8.5 7.4 373 73 4,411 3,840

Sources: (a) OECD Health Data (2010); (b) CEC (2008), annex 7, cost/bed/day corr; (c) Eurostat (2003); (d) population-weighted average, 2005 population data from OECD Health Data (2010).

For instance, based on Table 1, the average direct cost of a cardiac hospital admission is:

8.5 days x € 373 = € 3,171

and the corresponding indirect cost related to work loss is:

2 x 8.5 days x € 73 = € 1,241.

Overall, the unit economic value related to a cardiac hospital admission is € 4,412.

For city-specific valuation, the last two columns of Table 1 provide average hospitalisation costs computed following the same rationale but using country-specific average lengths of stay, cost per day of hospitalization and daily work loss.

Valuation of the benefits of EU legislation to reduce the sulphur content of fuels

The legislation has two potential effects on mortality: short-term and long-term. It has been decided that, to take a conservative standpoint, mortality effects will be considered as short-term effects. Consequently, a VOLY of €86,600 is applied to each premature deaths to compute the benefits of the legislation. The economic evaluation thus constitutes a lower bound of the mortality benefits of the legislation.

References


The Aphekom collaborative network

The authors would like to thank the Aphekom collaborative network for its invaluable contribution to the project, in particular:

▪ FRENCH INSTITUTE FOR PUBLIC HEALTH SURVEILLANCE, InVS, Saint-Maurice, France – Sylvia Medina, Kanwal Eshai, Christophe Declercq, Agnès Lefranc, Myriam Blanchard, Sophie Larrieu, Tek-Ang Lim, Alain Le Tertre, Laurence Pascal, Mathilde Pascal, Magali Corso, Aymeric Ung.

▪ UMEA UNIVERSITY, Umeå, Sweden – Bertil Forsberg, Lars Modig, Kadri Meister, Hans-Orru

▪ MEDICAL UNIVERSITY OF VIENNA, Austria – Hanns Moshammer, Manfred Neuberger, Daniela Haluza, Hans-Peter Hutter

▪ BARCELONA PUBLIC HEALTH AGENCY, Spain – Manuel Nebot, Anna Perez, Natalia Valero

▪ CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY, CREAL, Barcelona, Spain, SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE and UNIVERSITY OF BASEL, Basel, Switzerland – Nino Künzli, Laura Perez-Grau, Xavier Basagaña, David Agis Cherta

▪ DUBLIN INSTITUTE OF TECHNOLOGY, Ireland – Patrick Goodman, Susann Henschel

▪ ST. GEORGE’S, UNIVERSITY OF LONDON, United Kingdom – Richard Atkinson

▪ DEPARTMENT OF HYGIENE, EPIDEMIOLOGY AND MEDICAL STATISTICS, MEDICAL SCHOOL, UNIVERSITY OF ATHENS, Greece – Klea Katsouyanni, Antonis Analitis, Konstantina Dimakopoulou, Alexandros Gryparis, Eva Kougea, Xanthi Pedeli

▪ CENTRE OF ECONOMICS AND ETHICS FOR THE ENVIRONMENT AND DEVELOPMENT, C3ED, UNIVERSITY OF VERSAILLES SAINT-QUENTIN-EN-YVELINES, UVSQ, France – Yorghos Remvikos, Delphine Delalande, Jeroen Van der Sluijs, Martin O’Connor

▪ VALENCIAN SCHOOL FOR HEALTH STUDIES, EVES, AND CENTRE FOR RESEARCH ON PUBLIC HEALTH, CSISP, Valencia, Spain – Ferran Ballester, Carmen Ifíñiguez, Marisa Estarlich

▪ BRUSSELS INSTITUTE FOR THE MANAGEMENT OF THE ENVIRONMENT, Belgium – Catherine Bouland

▪ BASQUE FOUNDATION FOR HEALTH INNOVATION AND RESEARCH, Vitoria-Gasteiz, Spain – Teresa Martínez-Rueda, Koldo Cambra, Eva Alonso, Sausan Malla, Francisco Cirarda

▪ ANDALUSIAN SCHOOL OF PUBLIC HEALTH, EASP, Granada, Spain – Piedad Martin-Olmedo, Antonio Daponte, Alejandro Lopez-Ruiz, Marina Lacasaña, Pablo Sánchez-Villegas, Miguel Barranco

▪ NATIONAL INSTITUTE OF PUBLIC HEALTH, Bucharest, Romania – Emilia Maria Nicu, Bogdan Constantin Stolica, Ioana Pertache

▪ INSTITUTE OF PUBLIC HEALTH OF THE REPUBLIC OF SLOVENIA, Ljubljana, Slovenia – Peter Otorepec, Katarina Bitenc, Ana Hojs

▪ NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH, Budapest, Hungary – Anna Pálgy, János Bobvos, Gizella Nador

▪ ROME E HEALTH AUTHORITY, Italy – Francesco Forastiere, Giulia Cesaroni, Chiara Badaloni

The Aphekom Scientific Committee

▪ UNIVERSITY OF BATH, United Kingdom – Alistair Hunt

▪ INSTITUTE OF OCCUPATIONAL MEDICINE, Edinburgh, United Kingdom – Brian Miller, Fintan Hurley

▪ WHO EUROPEAN CENTRE FOR ENVIRONMENT & HEALTH, Bonn, Germany – Michal Krzyzanowski

▪ WHO EUROPEAN CENTRE FOR ENVIRONMENT & HEALTH, Rome, Italy – Martin Krayer Von Krauss

▪ EUROPEAN COMMISSION DG JOINT RESEARCH CENTRE, Ispra, Italy – Peter Pärt

▪ SPANISH NATIONAL RESEARCH COUNCIL, CSIC, Barcelona, Spain – Xavier Querol
Other Aphekom contributors

• BRUNEL UNIVERSITY, London, United Kingdom – Ariana Zeka
• NATIONAL CENTER FOR SCIENTIFIC RESEARCH, GREQAM AND IDEP, Marseille, France – Olivier Chanel
• REGIONAL HEALTH OBSERVATORY OF THE PARIS ILE-DE-FRANCE REGION, ORS, Paris, France – Sabine Host, Edouard Chatignoux
• SAKLAD CONSULTANTS FOR COMMUNICATIONS STRATEGY, Paris & New York – Michael Saklad
• STOCKHOLM ENVIRONMENT ADMINISTRATION – Christer Johansson and Boel Lövenheim
• WWAM WRITERS LTD., Birmingham, United Kingdom – Geoff Davies

Coordination

• FRENCH INSTITUTE FOR PUBLIC HEALTH SURVEILLANCE, InVS, France - Sylvia Medina
• UMEA UNIVERSITY, SWEDEN - Bertil Forsberg

Funding and support

The Aphekom project has been co-funded by the European Commission’s Programme on Community Action in the Field of Public Health (2003-2008) under Grant Agreement No. 2007105, and by the many national and local institutions that have dedicated resources to the fulfilment of this project.

To learn more

www.aphekom.org

Piedad Martín-Olmedo, principal investigador for Granada Aphekom centre
piedad.martin.easp@juntadeandalucia.es

ESCUELA ANDALUZA DE SALUD PÚBLICA (EASP)
CAMPUS UNIVERSITARIO DE CARTUJA
CUESTA DEL OBSERVATORIO, 4
18080 GRANADA (SPAIN)